Discover
MBX
MBX Biosciences, Inc. Common Stock
66.16
1 x 66.15
1 x 66.29
bid
ask
+
0.01
0.01%
12:33 PM
timesize
| Ytd | 109.75% | |
| 1y | 487.53% |
65.75
day range
67.53
9.63
52 week range
72.64
| Open | 67.53 | Prev Close | 66.15 | Low | 65.75 | High | 67.53 | Mkt Cap | 3.15B |
| Vol | 172.65K | Avg Vol | 811.86K | EPS | -2.25 | P/E | -29.40 | Forward P/E | -17.26 |
| Beta | 0.10 | Short Ratio | 5.52 | Inst. Own | 119.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 52.14 | 200-d Avg | 36.55 | 1yr Est | 88.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -0.74 | N/A | N/A | N/A |
| 2026-08-06 | 2026-06 | -0.63 | -0.78 | -0.15 | -23.32% |
| 2026-05-07 | 2026-03 | -0.62 | -0.51 | 0.11 | 17.74% |
| 2026-03-12 | 2025-12 | -0.64 | -0.49 | 0.15 | 23.44% |
| 2025-11-06 | 2025-09 | -0.73 | -0.63 | 0.1 | 13.70% |
| 2025-08-07 | 2025-06 | -0.77 | -0.58 | 0.19 | 24.68% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-29 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-05-12 | Barclays | Upgrade | Overweight | Overweight |
| 2026-05-12 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-05-11 | Truist Securities | Upgrade | Buy | Buy |
| 2026-01-28 | Barclays | Upgrade | Overweight | |
| 2026-01-16 | Guggenheim | Upgrade | Buy | Buy |
Profile
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-15 | BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-09-15 | BEHBAHANI ALI | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-09-15 | CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2024-09-15 | FRAZIER LIFE SCIENCES X, L.P. | Beneficial Owner of more than 10% of a Class of Security | 4.55M | Purchase |
| 2025-02-17 | GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2025-09-25 | HERON PATRICK J | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 6.65M | 451.14M | 13.81% |
| 2026-03-30 | Orbimed Advisors LLC. | 3.64M | 246.72M | 7.55% |
| 2026-03-30 | NEA Management Company, LLC | 3.61M | 245.13M | 7.51% |
| 2026-06-29 | Blackrock Inc. | 3.32M | 225.41M | 6.90% |
| 2026-03-30 | Wellington Management Group, LLP | 3.19M | 216.47M | 6.63% |
| 2026-03-30 | FMR, LLC | 2.94M | 199.17M | 6.10% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.16M | 78.59M | 2.41% |
| 2026-03-30 | MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 890.00K | 60.36M | 1.85% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 801.38K | 54.35M | 1.66% |
| 2026-03-30 | T. Rowe Price Health Sciences Fund, Inc. | 721.31K | 48.92M | 1.50% |
| 2026-06-29 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 614.60K | 41.68M | 1.28% |
| 2026-06-29 | Fidelity Select Portfolios-Select Health Care Portfolio | 600.00K | 40.69M | 1.25% |